ABBV250110P175000
- 0.08
- -0.12-60.00%
AbbVie Newsroom
AbbVie's Strategic Acquisition and Long-Term Growth Potential Justify Buy Rating Despite Short-Term EPS Adjustments
AbbVie Price Target Cut to $211.00/Share From $215.00 by Truist Securities
AbbVie Is Maintained at Buy by Truist Securities
AbbVie Analyst Ratings
Truist Financial Maintains AbbVie(ABBV.US) With Buy Rating, Announces Target Price $211
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $224
Piper Sandler has raised AbbVie's Target Price to $220.
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $191
AbbVie Analyst Ratings
B of A Securities Reinstates Neutral on AbbVie, Announces $191 Price Target
Citi Maintains AbbVie(ABBV.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)
TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $225
AbbVie: Strong Buy Rating Based on Growth Potential and Strategic Positioning
Positive Outlook for Aldeyra Therapeutics: Buy Rating Backed by Promising Reproxalap Prospects and Strategic Partnership With AbbVie
AbbVie: Resilient Market Position and Growth Potential Justify Buy Rating
Daiwa Securities Downgrades AbbVie to Neutral From Outperform, Adjusts Price Target to $180 From $210